Brief: Sandoz Completes Strategic Acquisition Of Just-Evotec Biologics EU Sas, Asserting Biosimilars Leadership
Dec 8 (Reuters) - Sandoz Group AG SDZ.S: SANDOZ COMPLETES STRATEGIC ACQUISITION OF JUST-EVOTEC BIOLOGICS EU SAS, ASSERTING BIOSIMILARS LEADERSHIP SANDOZ GROUP AG - STRENGTHENS POSITION TO CAPTURE PROJECTED >USD 300 BILLION BIOSIMILARS LOSS OF EXCLUSIVITY (LOE) MARKET OPPORTUNITY OVER NEXT DECADE SANDOZ GROUP AG - NO IMPACT ON 2025 GUIDANCE FROM ACQUISITION Source text: ID:nEQH0hH1a Further company coverage: SDZ.S (Gdansk Newsroom) (((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases